Q1 Earnings In Brief: Celgene, Alkermes, Novo Nordisk, Acorda, Alexion
Executive Summary
First quarter earnings are in full swing. Here is a look at what some companies are saying to analysts during their quarterly calls. Celgene talks up Revlimid; Alkermes bullish on Aristada launch; Victoza market share threatened by Trulicity; Acorda plans for Phase III in post-stroke; Soliris still backbone at Alexion.
You may also be interested in...
Alexion's Managed Access Agreement Only Partially Quashes Strensiq Cost Concerns
Alexion has only managed to convince NICE to recommend Strensiq for treatment in a limited patient population with pediatric-onset hypophosphatasia. The news is a step forward after NICE initially declined the drug altogether, but the new recommendations highlight the difficulties companies face when trying to justify high orphan drug prices.
Stockwatch: Earnings Move From Mediocre to Worse
There is now no sugar-coating of the first-quarter 2016 earnings season for life sciences companies. By the end of the previous week a few companies had reported results that didn't disappoint but also didn't blow off any socks. By contrast, the second full week of earnings reports majored in significant disappointment.
Will Novo's LEADER Trial Move GLP-1 To The Diabetes Front Line?
Novo Nordisk AS has an impressive victory with a benefit demonstrated in the LEADER cardiovascular outcomes study of its GLP-1 agonist Victoza (liraglutide) in high-risk type 2 diabetes, but the real test could be whether the magnitude of benefit is big enough to shift practice and expand use beyond the class's tiny base.